The Accelerating Medicines Partnership Parkinson’s disease (AMP PD) Knowledge Platform is a tool to explore and analyze whole genome sequencing, transcriptomics, and harmonized clinical data across a wide range of studies, simplifying cross-cohort analyses.
Within the portal you can explore a dataset, understand its contents, and build custom cohorts for deeper analysis using Jupyter notebooks. AMP PD is a public-private partnership between The Michael J. Fox Foundation, National Institutes of Health, the U.S. Food and Drug Administration, Aligning Science Across Parkinson’s (ASAP), and five companies (Bristol Myers-Squibb, GSK, Pfizer, Sanofi, and Verily). AMP PD is managed through the Foundation of the National Institutes of Health (FNIH).
AMP PD Datasets
-
BioFIND
BioFIND is an observational, cross-sectional study with plasma, DNA, and RNA data from blood, whole blood, blood pellet, and cerebrospinal fluid in 118 well-defined, moderately advanced people with Parkinson's and 88 control volunteers.
-
HBS
The Harvard Biomarkers Study (HBS) is a longitudinal, case-control study of people with memory and movement disorders as well as controls without neurologic disease. A total of 877 HBS participants met the criteria for inclusion in AMP PD.
-
PDBP
The Parkinson’s Disease Biomarkers Program (PDBP) includes clinical assessments and biosample data from 1,599 participants with Parkinson's disease or another parkinsonism as well as controls.
-
PPMI
The Parkinson’s Progressive Marker’s Initiative (PPMI) is an ongoing longitudinal observational study with more than 1,500 participants contributing comprehensive clinical and genetic data.
AMP PD Resources
- Webinar and Training Videos: AMP PD offers six webinars and training videos that explain how to use the platform and its components, including Google Cloud Platform (GCP), BigQuery, and Terra.
Coming Soon!
-
LBD
Lewy Body Dementia (LBD) genetic data was generated to extend modern gene discovery methods to LBD and create a genetic resource for the dementia research community.
-
STEADY-PD3
Data from the STEADY-PD3 trial includes measures of neurological function, Parkinson's severity, cognition, and mood.
-
SURE-PD3
SURE-PD3 (Study of Urate Elevation in Parkinson's Disease) clinical trial data includes neurological function, Parkinson's severity, cognition, and mood.
-
LCC
LRRK2 Cohort Consortium (LCC) includes motor and non-motor clinical assessments data as well as genetic data generated from whole blood samples.